🇺🇸 FDA
Pipeline program

JNJ-67953964

67953964MDD3003

Phase 3 small_molecule active

Quick answer

JNJ-67953964 for Major Depressive Disorder is a Phase 3 program (small_molecule) at Janssen-Cilag International N.V. with 1 ClinicalTrials.gov record(s).

Program details

Company
Janssen-Cilag International N.V.
Indication
Major Depressive Disorder
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials